NCT02597803View on ClinicalTrials.gov

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Dry Eye Syndrome
Interventions
DRUG

RGN-259

A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days

DRUG

Placebo

It is composed of the same excipients as RGN-259 but does not contain Tβ4

Trial Locations (1)

01810

Andover, MA, Andover

All Listed Sponsors
lead

ReGenTree, LLC

INDUSTRY

NCT02597803 - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 | Biotech Hunter | Biotech Hunter